Swine Vaccines Market Size, Share & Trends Analysis Report By Product (Recombinant, Inactivated), By Type (Pseudorabies, Porcine Circovirus Type 2), By Region (Asia Pacific, North America), And Segment Forecasts, 2021 - 2028

Report Overview

The global swine vaccines market size was valued at USD 1.45 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 4.9% from 2021 to 2028. Swine production is a key component of global food security, agricultural countries, and local & international business. Contagious diseases impact pig health and stability and productivity of the swine industry globally. Thus, the rising prevalence of diseases in swine is estimated to drive the market over the forecast years. Porcine Parvovirus (PPV) is a reproductive disease present in most pig farms globally. Porcine Reproductive and Respiratory Syndrome (PRRS) remains to be a highly prevalent disease in pig farms affecting economic losses through its adverse effects on reproduction and growth as well as by clinical illness.

Thus, it led to continuous innovation in the market to meet customer demand. For instance, in October 2019, Boehringer Ingelheim gained authorization from EMA for ReprocycParvoFLEX. This is the first subunit porcine parvovirus vaccine to protect swine fetuses against transplacental infection. Instituting a pig vaccination program supports to protect from infectious diseases at all stages of development. Thus, companies are focused on delivering vaccination services to appropriately use swine vaccines, which helps farming bottom line whether it's managing bacteria or viruses.

For instance, HIPRA offers a range of services to cater to the demand. HIPRA link Vaccination is a professional APP devised by HIPRA, which records all vaccination data produced by a smart device (Hipraspray, Hipradermic, and Hipraject), allowing one to manage, control, and analyze own vaccination activity. This app is available for Swine and Poultry vaccinations. Thus, demand for better swine vaccines is further boosting the market growth.

The COVID-19 pandemic has had a significant impact on the market. Considering this global challenge, the pharmaceutical industry has expanded its research at an unprecedented pace. For example, the R&D unit of Boehringer Ingelheim Animal Health business was renamed Animal Health Global Innovation and given a new administrative structure, which is based on disease and system-centered R&D approach. This allows the company to bring innovations in treatment as well as preventive veterinary therapies to the market.

The surge in the demand for animal protein, together with the increasing user inclination for a low-fat and high-protein diet, has headed to a significant upsurge in the intake of animal protein, including pork, across the globe. As the world populace is expected to reach 9.8 billion in 2050, animal health becomes essential to guarantee both animal well-being and the worldwide protein supply. This is expected to augment the vaccine demand to protect animals from diseases. Moreover, the current industry trend of antibiotic-free production is further increasing the demand.

Product Insights

The inactivated vaccines segment dominated the global market in 2020 with a revenue share of more than 38% in 2020. This is attributed to the easy availability, low cost, minimal risk of revert reaction of killed viruses, and new improvements by key players. PARVOVAX and PROGRESSIS from Ceva are an inactivated vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome, respectively.

The recombinant vaccine segment is expected to exhibit the fastest CAGR from 2021 to 2028. These vaccines are anticipated to assist in achieving vaccination against several virus strains, as recombinants can carry numerous gene inserts. IngelvacCircoFLEX from Boehringer Ingelheim International GmbH is a recombinant vaccine, in which, porcine circovirus type 2, and PCV 2 are active ingredients.

Type Insights

The Porcine Circovirus type 2 (PCV2) dominated the global market with a revenue share of more than 14% in 2020. Transmission of PCV-2 may be by direct contact with an infected pig. PCV2 is the quickly mutating of all single-stranded DNA (ssDNA) viruses and thus, has a great mutation and recombination rate. The PCV2 is one of the most significant infectious agents on pig productivity around the world, including India, China, Malaysia, and Thailand. Therefore, contributing to the major market share during the forecast period.

The foot & mouth disease segment is expected to witness the second-fastest CAGR over the forecast period. In swine, foot-and-mouth disease is an epidemic that has a substantial effect on food safety and animal husbandry. This is a main viral disease, affecting the national and international trade of animal products and leading to great economic losses and social concerns. Foot-and-mouth disease type can affect all pigs. Hence, routine vaccination would help prevent the disease. In addition, reintroduction of a virus is always possible, as the virus is widespread in many parts of the globe. Thus, supports overall market growth.

Regional Insights

Asia Pacific accounted for the maximum revenue share of more than 46% in 2020 and is anticipated to register the fastest CAGR during the forecast period. Middle-income nations, especially Southeast Asian countries, consume greater amounts of meat and the meat consumption of pork is still on the rise. Moreover, rising infectious diseases, such as Classical Swine Fever (CSF), in the region further boost product demand. CSF causes a loss of about 400 crores per annum in India. Thus, the government of India is more focused on developing new vaccines. For instance, in February 2020, ICAR-Indian Veterinary Research Institute has introduced a new locally created vaccine for managing CSF, which costs only Rs. 2 per dose.

North America held a significant revenue share in 2020. The presence of well-established veterinary healthcare infrastructure, increased demand for animal protein, highly organized farming structure, and rising expenditure on animal health is attributed to the region’s growth. Countries, such as the U.S. and Canada, have developed and well-defined healthcare systems and a high concentration of key players. For instance, in September 2020, Pharmgate Animal Health announced PRRSGard, a recombinant chimeric vaccine for Porcine Reproductive and Respiratory Syndrome, which is available largely in the U.S. market.

Key Companies & Market Share Insights

The market is highly competitive and marked by the existence of several small- and large-scale manufacturers. These players are constantly involved in strategic initiatives, such as new product launches, regional expansions, joint ventures, mergers, and acquisitions, to gain deeper market penetration. For instance, in February 2021, Algenex SL and Virbac proclaimed that they have entered an international licensing agreement for the development and commercialization of a CrisBio-based vaccine in a key swine indication.

The vaccine will be created together and manufactured using CrisBio, Algenex’s patented protected Baculovirus vector-mediated expression platform, which leverages the power of insects to function as natural single-use bioreactors. In June 2020, Boehringer Ingelheim received a New Veterinary Drug Registration Certificate from the Ministry of Agriculture and Rural Affairs of China for Ingelvac CSF MLV. This is the first CSF live vaccine developed jointly by Chinese research institutes and multinational companies. Some of the prominent players in the global swine vaccines market include:

• Merck Animal Health

• Ceva

• Zoetis

• Boehringer Ingelheim GmbH

• Elanco

• Indian Immunologicals Ltd.

• BiogénesisBagó

• Phibro Animal Health

• KM Biologics

• HIPRA

Swine Vaccines Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research has segmented the global swine vaccines market report on the basis of product, type, and region:

• Type Outlook (Revenue, USD Million, 2016 - 2028)

  • Swine Influenza

  • Classical Swine Fever

  • Porcine Parvovirus

  • Porcine Circovirus Type 2

  • M.Hyo

  • ActinobacillusPleuropneumonia

  • PRRS

  • Foot & Mouth Disease

  • Pseudorabies

  • PEDV

  • Others

• Product Outlook (Revenue, USD Million, 2016 - 2028)

  • Attenuated Live Vaccines

  • Inactivated Vaccines

  • Subunit Vaccines

  • DNA Vaccines

  • Recombinant Vaccines

• Regional Outlook (Revenue, USD Million, 2016 - 2028)

  • North America

    • U.S.

    • Canada

  •  Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa (MEA)

    • Saudi Arabia

    • South Africa